NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Cumberland Pharmaceuticals Inc. CPIX
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$44.5M
▲ 17.6% vs FY2024
EPS · FY25
$-0.19
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-11.9%
Net margin · FY25
-6.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 44.5M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 6 cents on every revenue dollar this year.
Per share
USD -0.19
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-11.9%
Return on equity, FY2025
ROE
Operating margin-6.3%
Net margin-6.4%
Return on assets-3.7%
Each USD of equity lost 12 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD -4.5M
Share of profit-0.0%
Consecutive raises—
Growth
+4.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+2.0%
+4.4%
+47.7%
−0.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years−0.2%
Change, 10 years−8.7%
The share count shrank 0% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 76.8M
total assets, end of FY2025
Total assetsUSD 76.8M
EquityUSD 24.9M
CashUSD 11.4M
Gross debtUSD 0.00
Net debtUSD -11.4M
Current ratio1.01×
The company holds more cash than debt.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.1
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
EBITDA $B
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
Income tax $B
0.0
−0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
EPS, diluted $
−0.19
−0.46
−0.44
−0.38
−0.24
−0.22
−0.23
−0.45
−0.50
−0.06
0.04
0.14
−0.11
0.30
0.28
0.12
0.17
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−11.9
−24.7
−19.1
−14.1
−7.8
−6.8
−6.6
−11.6
−11.6
−1.3
0.9
3.0
−2.5
6.9
7.0
3.2
·
Shares out B
0.01
0.01
0.01
0.01
0.01
0.01
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
49 of 49
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed